Design Synthesis Characterization and Biological Evaluation of Novel 5 Oxo Imidazolines As a Potent Polo Like Kinase 1 Inhibitors

Abstract

Cancer has emerged as a deadliest disease, and the different types of cancer such as lung, stomach, breast, and prostate cancer are life-threatening. Breast cancer has surpassed lung cancer in its incidence. The causative factors include family history, age, lifestyle disorders such as obesity, physical inactivity etc., where in approximately 75% is due to the expression of cancer Several polo-like kinase 1 (PLK1) inhibitors have been evaluated in clinical trials, including BI2536, volasertib, and onvansertib, none have been granted marketing approval yet. These inhibitors are being investigated as potential cancer therapies newlinePolo like kinase 1 inhibitors are also under study to significantly reduce breast malignancies. Oxadiazole is the widely explored pharmacophore in the development of Zibotentan. The previous literature studies suggest that nucleus oxadiazole and 5-oxo-imidazoline with aromatic aldehyde substitution had shown superior efficacy as Polo like kinase 1 inhibitors newline